By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celldex Therapeutics, Inc. 

222 Cameron Drive
Suite 400
Phillipsburg  New Jersey  08865  U.S.A.
Phone: 908-454-7120 Fax: 908-454-1911



Company News
Celldex (CLDX) Initiates Phase I/II Study Of Varlilumab In Combination With Atezolizumab In Renal Cell Carcinoma 12/8/2015 7:36:47 AM
Celldex (CLDX) Cancer Vaccine Extends Life for Those With Brain Cancer 11/23/2015 6:26:14 AM
Celldex (CLDX) Presents Varlilumab Mechanism Data At SITC Annual Meeting 2015 11/6/2015 8:01:20 AM
Celldex (CLDX) Reports Third Quarter 2015 Results 11/6/2015 7:17:47 AM
Celldex (CLDX) To Present At The Leerink Partners Immuno-Oncology Roundtable 10/1/2015 8:16:27 AM
Celldex (CLDX) Reports Second Quarter 2015 Results 8/11/2015 12:20:40 PM
Celldex (CLDX) To Report Second Quarter 2015 Financial Results And Host Corporate 2015 Objectives Update Call 8/4/2015 8:02:14 AM
Celldex (CLDX) To Present At The Cantor Fitzgerald Inaugural Healthcare Conference 7/2/2015 7:43:54 AM
Independent Data Safety And Monitoring Board Recommends Continuation Of Celldex (CLDX)'s Phase III Study Of RINTEGA (Rindopepimut) In Newly Diagnosed Glioblastoma 6/29/2015 7:29:58 AM
ASCO15: Celldex (CLDX) Release: Randomized Phase 2 React Study Of RINTEGA In Recurrent Bevacizumab-Naive Glioblastoma Demonstrates Statistically Significant Overall Survival And Emergence Of Long-Term Survival Benefit; Primary Endpoint Of PFS6 Met 6/1/2015 5:54:56 AM